244 related articles for article (PubMed ID: 35658010)
1. An innate IL-25-ILC2-MDSC axis creates a cancer-permissive microenvironment for
Jou E; Rodriguez-Rodriguez N; Ferreira AF; Jolin HE; Clark PA; Sawmynaden K; Ko M; Murphy JE; Mannion J; Ward C; Matthews DJ; Buczacki SJA; McKenzie ANJ
Sci Immunol; 2022 Jun; 7(72):eabn0175. PubMed ID: 35658010
[TBL] [Abstract][Full Text] [Related]
2. Group 2 innate lymphoid cells promote TNBC lung metastasis via the IL-13-MDSC axis in a murine tumor model.
Zhao N; Zhu W; Wang J; Liu W; Kang L; Yu R; Liu B
Int Immunopharmacol; 2021 Oct; 99():107924. PubMed ID: 34217145
[TBL] [Abstract][Full Text] [Related]
3. Obesity correlates with the immunosuppressive ILC2s-MDSCs axis in advanced breast cancer.
Liu W; Li B; Liu D; Zhao B; Sun G; Ding J
Immun Inflamm Dis; 2024 Mar; 12(3):e1196. PubMed ID: 38501542
[TBL] [Abstract][Full Text] [Related]
4. The IL-25/ILC2 axis promotes lung cancer with a concomitant accumulation of immune-suppressive cells in tumors in humans and mice.
Bahhar I; Eş Z; Köse O; Turna A; Günlüoğlu MZ; Çakır A; Duralı D; Magnusson FC
Front Immunol; 2023; 14():1244437. PubMed ID: 37781372
[TBL] [Abstract][Full Text] [Related]
5. A novel type-2 innate lymphoid cell-based immunotherapy for cancer.
Saranchova I; Xia CW; Besoiu S; Finkel PL; Ellis SLS; Kari S; Munro L; Pfeifer CG; Fazli L; Gleave ME; Jefferies WA
Front Immunol; 2024; 15():1317522. PubMed ID: 38524132
[TBL] [Abstract][Full Text] [Related]
6. Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis.
Trabanelli S; Chevalier MF; Martinez-Usatorre A; Gomez-Cadena A; Salomé B; Lecciso M; Salvestrini V; Verdeil G; Racle J; Papayannidis C; Morita H; Pizzitola I; Grandclément C; Bohner P; Bruni E; Girotra M; Pallavi R; Falvo P; Leibundgut EO; Baerlocher GM; Carlo-Stella C; Taurino D; Santoro A; Spinelli O; Rambaldi A; Giarin E; Basso G; Tresoldi C; Ciceri F; Gfeller D; Akdis CA; Mazzarella L; Minucci S; Pelicci PG; Marcenaro E; McKenzie ANJ; Vanhecke D; Coukos G; Mavilio D; Curti A; Derré L; Jandus C
Nat Commun; 2017 Sep; 8(1):593. PubMed ID: 28928446
[TBL] [Abstract][Full Text] [Related]
7. Emerging roles for IL-25 and IL-33 in colorectal cancer tumorigenesis.
Jou E; Rodriguez-Rodriguez N; McKenzie ANJ
Front Immunol; 2022; 13():981479. PubMed ID: 36263033
[TBL] [Abstract][Full Text] [Related]
8. ILC2-derived IL-9 inhibits colorectal cancer progression by activating CD8
Wan J; Wu Y; Huang L; Tian Y; Ji X; Abdelaziz MH; Cai W; Dineshkumar K; Lei Y; Yao S; Sun C; Su Z; Wang S; Xu H
Cancer Lett; 2021 Apr; 502():34-43. PubMed ID: 33429004
[TBL] [Abstract][Full Text] [Related]
9. Enhanced Apc
Guo B; Zheng Y; Fan Y; Yang Y; Wang Y; Qin L; An Y; Xu X; Zhang X; Sun G; Dou H; Shao C; Gong Y; Jiang B; Hu H
Neoplasia; 2024 Jul; 53():101005. PubMed ID: 38761506
[TBL] [Abstract][Full Text] [Related]
10. IL-33-ILC2 axis promotes anti-tumor CD8
Okuyama Y; Okajima A; Sakamoto N; Hashimoto A; Tanabe R; Kawajiri A; Kawabe T; Ishii N
Biochem Biophys Res Commun; 2022 Dec; 637():9-16. PubMed ID: 36375254
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-33 Induces the Enzyme Tryptophan Hydroxylase 1 to Promote Inflammatory Group 2 Innate Lymphoid Cell-Mediated Immunity.
Flamar AL; Klose CSN; Moeller JB; Mahlakõiv T; Bessman NJ; Zhang W; Moriyama S; Stokic-Trtica V; Rankin LC; Putzel GG; Rodewald HR; He Z; Chen L; Lira SA; Karsenty G; Artis D
Immunity; 2020 Apr; 52(4):606-619.e6. PubMed ID: 32160524
[TBL] [Abstract][Full Text] [Related]
12. Group 2 innate lymphoid cells contribute to IL-33-mediated alleviation of cardiac fibrosis.
Chen WY; Wu YH; Tsai TH; Li RF; Lai AC; Li LC; Yang JL; Chang YJ
Theranostics; 2021; 11(6):2594-2611. PubMed ID: 33456562
[No Abstract] [Full Text] [Related]
13. Group 2 innate lymphoid cells (ILC2s) are important in typical type 2 immune-mediated diseases and an essential therapeutic target.
Jin J; Sunusi S; Lu H
J Int Med Res; 2022 Jan; 50(1):3000605211053156. PubMed ID: 35048721
[TBL] [Abstract][Full Text] [Related]
14. The NF-κB Transcription Factor c-Rel Modulates Group 2 Innate Lymphoid Cell Effector Functions and Drives Allergic Airway Inflammation.
Mindt BC; Krisna SS; Duerr CU; Mancini M; Richer L; Vidal SM; Gerondakis S; Langlais D; Fritz JH
Front Immunol; 2021; 12():664218. PubMed ID: 34867937
[TBL] [Abstract][Full Text] [Related]
15. Eosinophils promote effector functions of lung group 2 innate lymphoid cells in allergic airway inflammation in mice.
LeSuer WE; Kienzl M; Ochkur SI; Schicho R; Doyle AD; Wright BL; Rank MA; Krupnick AS; Kita H; Jacobsen EA
J Allergy Clin Immunol; 2023 Aug; 152(2):469-485.e10. PubMed ID: 37028525
[TBL] [Abstract][Full Text] [Related]
16. Combination of IL-33 with PD-1 blockade augment mILC2s-mediated anti-tumor immunity.
Yue J; Guo H; Xu P; Ma J; Shi W; Wu Y
Cancer Immunol Immunother; 2024 Mar; 73(4):65. PubMed ID: 38430390
[TBL] [Abstract][Full Text] [Related]
17. Lung group 2 innate lymphoid cells are trained by endogenous IL-33 in the neonatal period.
Steer CA; Mathä L; Shim H; Takei F
JCI Insight; 2020 Jul; 5(14):. PubMed ID: 32573494
[TBL] [Abstract][Full Text] [Related]
18. Interferon-γ constrains cytokine production of group 2 innate lymphoid cells.
Kudo F; Ikutani M; Seki Y; Otsubo T; Kawamura YI; Dohi T; Oshima K; Hattori M; Nakae S; Takatsu K; Takaki S
Immunology; 2016 Jan; 147(1):21-9. PubMed ID: 26425820
[TBL] [Abstract][Full Text] [Related]
19. Lung group 2 innate lymphoid cells differentially depend on local IL-7 for their distribution, activation, and maintenance in innate and adaptive immunity-mediated airway inflammation.
Takami D; Abe S; Shimba A; Asahi T; Cui G; Tani-Ichi S; Hara T; Miyata K; Ikutani M; Takatsu K; Oike Y; Ikuta K
Int Immunol; 2023 Nov; 35(11):513-530. PubMed ID: 37493250
[TBL] [Abstract][Full Text] [Related]
20. Crosstalk between ILC2s and Th2 cells varies among mouse models.
Gurram RK; Wei D; Yu Q; Butcher MJ; Chen X; Cui K; Hu G; Zheng M; Zhu X; Oh J; Sun B; Urban JF; Zhao K; Leonard WJ; Zhu J
Cell Rep; 2023 Feb; 42(2):112073. PubMed ID: 36735533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
